PetMed Express Crescita futura

Future criteri di controllo 3/6

PetMed Express is forecast to grow earnings and revenue by 60.7% and 2.2% per annum respectively. EPS is expected to grow by 59.8% per annum. Return on equity is forecast to be 2.1% in 3 years.

Informazioni chiave

60.7%

Tasso di crescita degli utili

59.8%

Tasso di crescita dell'EPS

Specialty Retail crescita degli utili	9.6%
Tasso di crescita dei ricavi	2.2%
Rendimento futuro del capitale proprio	2.1%
Copertura analitica	Low
Ultimo aggiornamento	09 Sep 2024

Aggiornamenti recenti sulla crescita futura

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 09

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Jun 14

Recent updates

Optimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking

Oct 04

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 09

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Jun 14

PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price

Jun 12

PetMed Express CFO to leave post today, by remain with company over transition period

Aug 02

PetMed Express' (NASDAQ:PETS) Dividend Will Be $0.30

Jul 29

PetMed Express FQ1 2023 Earnings Preview

Jul 24

PetMeds becomes exclusive U.S. fulfillment partner for Vetster, telemedicine platform

Jul 15

Returns On Capital At PetMed Express (NASDAQ:PETS) Paint A Concerning Picture

Jul 04

PetMed Express: 'AutoShip & Save' Program Key Driver Of Growth

May 26

PetMed Express (NASDAQ:PETS) Has Affirmed Its Dividend Of US$0.30

May 13

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:PETS - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	289	2	N/A	N/A	1
3/31/2026	275	-1	N/A	N/A	2
3/31/2025	266	2	N/A	N/A	2
6/30/2024	271	-3	-9	-5	N/A
3/31/2024	281	-7	0	4	N/A
12/31/2023	277	-3	2	7	N/A
9/30/2023	270	-1	17	22	N/A
6/30/2023	265	1	17	22	N/A
3/31/2023	257	5	23	28	N/A
12/31/2022	259	9	23	27	N/A
9/30/2022	261	13	19	23	N/A
6/30/2022	263	17	23	25	N/A
3/31/2022	272	19	17	18	N/A
12/31/2021	279	22	26	28	N/A
9/30/2021	284	25	24	26	N/A
6/30/2021	292	27	48	51	N/A
3/31/2021	304	24	38	40	N/A
12/31/2020	312	31	37	39	N/A
9/30/2020	306	30	34	37	N/A
6/30/2020	300	28	25	28	N/A
3/31/2020	284	26	37	39	N/A
12/31/2019	274	25	33	35	N/A
9/30/2019	275	26	41	42	N/A
6/30/2019	276	31	23	23	N/A
3/31/2019	283	38	45	45	N/A
12/31/2018	286	41	34	34	N/A
9/30/2018	286	43	39	39	N/A
6/30/2018	282	41	45	46	N/A
3/31/2018	274	37	N/A	37	N/A
12/31/2017	270	35	N/A	51	N/A
9/30/2017	262	30	N/A	38	N/A
6/30/2017	256	27	N/A	48	N/A
3/31/2017	249	24	N/A	47	N/A
12/31/2016	242	22	N/A	30	N/A
9/30/2016	240	22	N/A	35	N/A
6/30/2016	236	21	N/A	23	N/A
3/31/2016	235	21	N/A	21	N/A
12/31/2015	229	20	N/A	25	N/A
9/30/2015	228	20	N/A	22	N/A
6/30/2015	228	18	N/A	29	N/A
3/31/2015	229	17	N/A	32	N/A
12/31/2014	228	17	N/A	25	N/A
9/30/2014	229	17	N/A	13	N/A
6/30/2014	232	18	N/A	8	N/A
3/31/2014	233	18	N/A	14	N/A
12/31/2013	236	18	N/A	9	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: PETS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Guadagni vs Mercato: PETS is forecast to become profitable over the next 3 years, which is considered above average market growth.

Guadagni ad alta crescita: PETS is expected to become profitable in the next 3 years.

Ricavi vs Mercato: PETS's revenue (2.2% per year) is forecast to grow slower than the US market (8.9% per year).

Ricavi ad alta crescita: PETS's revenue (2.2% per year) is forecast to grow slower than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: PETS's Return on Equity is forecast to be low in 3 years time (2.1%).

PetMed Express Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased by 21% to US$7.75

Price target decreased by 18% to US$15.00

Consensus EPS estimates fall by 31%, revenue upgraded

Consensus EPS estimates fall by 20%

Recent updates

PetMed Express, Inc. to Report Q2, 2025 Results on Nov 06, 2024

Optimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking

PetMed Express, Inc. Appoints Robyn DElia as Chief Financial Officer, Effective September 16, 2024

New major risk - Revenue and earnings growth

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

New minor risk - Share price stability

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Petmed Express, Inc. Appoints Doug Krulik as Chief Accounting Officer, Effective August 19, 2024

PetMed Express, Inc. to Report Q1, 2025 Results on Aug 06, 2024

PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000 Index

PetMed Express, Inc., Annual General Meeting, Aug 08, 2024

PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Full year 2024 earnings: EPS misses analyst expectations

New major risk - Revenue and earnings growth

PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price

PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024

PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer

PetMed Express, Inc. to Report Q4, 2024 Results on Jun 11, 2024

PetMed Express, Inc. Appoints Justin Mennen to Board of Directors, Effective June 3, 2024

Price target decreased by 21% to US$7.75

PetMed Express, Inc. Announces Executive Changes

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. to Report Q3, 2024 Results on Feb 08, 2024

PetMed Express, Inc. Announces Management Changes

Independent Chairman of the Board recently bought US$301k worth of stock

CEO, President & Director recently bought US$101k worth of stock

PetMed Express, Inc. Makes Decision to Suspend the Quarterly Dividend Effective the Quarter Ended September 30, 2023

PetMed Express, Inc. to Report Q2, 2024 Results on Oct 30, 2023

Price target decreased by 18% to US$15.00

Now 21% undervalued after recent price drop

A Look At The Fair Value Of PetMed Express, Inc. (NASDAQ:PETS)

PetMed Express (NASDAQ:PETS) Is Paying Out A Dividend Of $0.30

Upcoming dividend of US$0.30 per share at 9.0% yield

First quarter 2024 earnings: EPS and revenues miss analyst expectations

PetMed Express, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

High number of new directors

Consensus EPS estimates fall by 31%, revenue upgraded

Upcoming dividend of US$0.30 per share at 8.1% yield

Full year 2023 earnings: EPS and revenues miss analyst expectations

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on June 12, 2023

PetMed Express, Inc., Annual General Meeting, Aug 03, 2023

Now 22% undervalued after recent price drop

PetMed Express, Inc. Appoints Sandra Y. Campos to its Board of Directors

PetMed Express, Inc. to Report Q4, 2023 Results on May 22, 2023

Consensus EPS estimates fall by 20%

The Returns On Capital At PetMed Express (NASDAQ:PETS) Don't Inspire Confidence

Consensus EPS estimates fall by 48%

PetMed Express (NASDAQ:PETS) Will Pay A Dividend Of $0.30

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.21 profit in 3Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on February 27, 2023

Investor sentiment improves as stock rises 16%

PetMed Express, Inc. to Report Q3, 2023 Results on Feb 06, 2023

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

PetMed Express (NASDAQ:PETS) Will Pay A Dividend Of $0.30

Price target decreased to US$20.67

PetMed Express, Inc. Declares Quarterly Dividend, Payable on November 30, 2022

Price target decreased to US$21.33

PetMed Express, Inc. to Report Q2, 2023 Results on Nov 07, 2022

PetMed Express Puts Are Compelling

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.30 per share

Now 23% undervalued after recent price drop

PetMed Express CFO to leave post today, by remain with company over transition period

Consensus EPS estimates fall by 15%